Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV001947519 | SCV002127508 | pathogenic | Microcephaly, normal intelligence and immunodeficiency | 2021-09-29 | criteria provided, single submitter | clinical testing | For these reasons, this variant has been classified as Pathogenic. This variant has not been reported in the literature in individuals with NBN-related conditions. This variant is not present in population databases (ExAC no frequency). This sequence change creates a premature translational stop signal (p.Ser630*) in the NBN gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in NBN are known to be pathogenic (PMID: 9590180, 16415040). |
Ambry Genetics | RCV002406960 | SCV002723845 | pathogenic | Hereditary cancer-predisposing syndrome | 2020-02-25 | criteria provided, single submitter | clinical testing | The p.S630* pathogenic mutation (also known as c.1889C>A), located in coding exon 12 of the NBN gene, results from a C to A substitution at nucleotide position 1889. This changes the amino acid from a serine to a stop codon within coding exon 12. This alteration is expected to result in loss of function by premature protein truncation or nonsense-mediated mRNA decay. As such, this alteration is interpreted as a disease-causing mutation. |
Baylor Genetics | RCV004571457 | SCV005056127 | likely pathogenic | Aplastic anemia | 2024-03-05 | criteria provided, single submitter | clinical testing |